{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:17:24Z","timestamp":1776226644085,"version":"3.50.1"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,5]]},"abstract":"<jats:p>Prior research suggested the potential correlation between circulating immune cell phenotypes and prostate cancer (PCa). However, it remains unclear whether the correlation can be mediated by plasma metabolites. We performed a bidirectional 2-sample, 2-step Mendelian randomization (MR) study mainly utilizing the inverse variance weighted method to examine the causal role of circulating immunophenotypes on PCa and explore the mediation effect of plasma metabolites in the pathway from immunophenotypes to PCa. MR analyses revealed that 7 circulating immune cell phenotypes and 9 plasma metabolites were significantly related to the risk of PCa. Notably, the mediation MR analysis revealed that X-12100 levels accounted for 10.5% of the decreased risk of PCa associated with CD4\u2005+\u2005CD8dim AC in TBNK panel, and X-24418 levels accounted for 11.8% of the elevated risk of PCa related to FSC-A on granulocyte in cDC panel. Our study established a causal relationship between immunophenotypes and PCa, and unveiled the mediating role of plasma metabolites in this association. Meanwhile, we emphasized the notable impact of the immune-metabolite axis on PCa, and immune cells may promote or inhibit tumor progression by influencing metabolite levels, providing a novel insight for studying the pathogenic mechanisms of PCa.<\/jats:p>","DOI":"10.1097\/md.0000000000044282","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:04:02Z","timestamp":1757354642000},"page":"e44282","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Plasma metabolites mediate the effects of circulating immune cell phenotypes on prostate cancer: A 2-step Mendelian randomization study"],"prefix":"10.1097","volume":"104","author":[{"given":"Wenjie","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Shen","sequence":"additional","affiliation":[{"name":"Research Center for Experimental Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanyu","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4175-1009","authenticated-orcid":false,"given":"Danfeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251029","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 update on prostate cancer epidemiology and risk factors \u2013 a systematic review.","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"key":"R2-20251029","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates.","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"R3-20251029","first-page":"17","article-title":"Cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R4-20251029","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"403","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"key":"R5-20251029","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.semcancer.2021.09.007","article-title":"Microbiota and prostate cancer.","volume":"86","author":"Rizzo","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R6-20251029","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.23.00723","article-title":"Early treatment intensification in metastatic hormone-sensitive prostate cancer.","volume":"41","author":"Wala","year":"2023","journal-title":"J Clin Oncol"},{"key":"R7-20251029","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41585-021-00470-4","article-title":"Treatment and trials in non-metastatic castration-resistant prostate cancer.","volume":"18","author":"Lokeshwar","year":"2021","journal-title":"Nat Rev Urol"},{"key":"R8-20251029","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/cancers13030546","article-title":"Bone targeting agents in patients with metastatic prostate cancer: state of the art.","volume":"13","author":"Mollica","year":"2021","journal-title":"Cancers"},{"key":"R9-20251029","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.3390\/cancers16213689","article-title":"Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: a systematic review and meta-analysis.","volume":"16","author":"Sahin","year":"2024","journal-title":"Cancers"},{"key":"R10-20251029","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S1470-2045(17)30327-3","article-title":"Evolving adoptive cellular therapies in urological malignancies.","volume":"18","author":"Wong","year":"2017","journal-title":"Lancet Oncol"},{"key":"R11-20251029","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13045-019-0788-4","article-title":"TCR-like antibodies in cancer immunotherapy.","volume":"12","author":"He","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R12-20251029","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41585-023-00834-y","article-title":"Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer.","volume":"21","author":"S\u00e9guier","year":"2023","journal-title":"Nat Rev Urol"},{"key":"R13-20251029","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1038\/s41388-019-0688-7","article-title":"Lactate modulates CD4+ T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8\/miR21 axis.","volume":"38","author":"Comito","year":"2019","journal-title":"Oncogene"},{"key":"R14-20251029","first-page":"624","article-title":"Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data.","volume":"31","author":"Guven","year":"2023","journal-title":"Support Care Cancer"},{"key":"R15-20251029","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2021.10.027","article-title":"The evolving role of immune cells in prostate cancer.","volume":"525","author":"Wang","year":"2022","journal-title":"Cancer Lett"},{"key":"R16-20251029","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/ijms22041551","article-title":"Treating prostate cancer by antibody\u2013drug conjugates.","volume":"22","author":"Rosellini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R17-20251029","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","article-title":"Metabolism of immune cells in cancer.","volume":"20","author":"Leone","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"R18-20251029","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41591-019-0404-8","article-title":"The landscape of cancer cell line metabolism.","volume":"25","author":"Li","year":"2019","journal-title":"Nat Med"},{"key":"R19-20251029","doi-asserted-by":"crossref","first-page":"k601","DOI":"10.1136\/bmj.k601","article-title":"Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians.","volume":"362","author":"Davies","year":"2018","journal-title":"BMJ"},{"key":"R20-20251029","doi-asserted-by":"crossref","first-page":"1358416","DOI":"10.3389\/fendo.2024.1358416","article-title":"Association between circulating immune cells and the risk of prostate cancer: a Mendelian randomization study.","volume":"15","author":"Hao","year":"2024","journal-title":"Front Endocrinol"},{"key":"R21-20251029","doi-asserted-by":"crossref","first-page":"1381920","DOI":"10.3389\/fcell.2024.1381920","article-title":"Causal relationship between immune cells and prostate cancer: a Mendelian randomization study.","volume":"12","author":"Ye","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"R22-20251029","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10654-021-00757-1","article-title":"Mendelian randomisation for mediation analysis: current methods and challenges for implementation.","volume":"36","author":"Carter","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"R23-20251029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-publhealth-032315-021402","article-title":"Mediation analysis: a practitioner\u2019s guide.","volume":"37","author":"VanderWeele","year":"2016","journal-title":"Annu Rev Public Health"},{"key":"R24-20251029","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1081\/BIP-120022775","article-title":"On non-inferiority analysis based on delta-method confidence intervals.","volume":"13","author":"Rothmann","year":"2007","journal-title":"J Biopharm Stat"},{"key":"R25-20251029","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41588-020-0684-4","article-title":"Complex genetic signatures in immune cells underlie autoimmunity and inform therapy.","volume":"52","author":"Orr\u00f9","year":"2020","journal-title":"Nat Genet"},{"key":"R26-20251029","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41588-022-01270-1","article-title":"Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases.","volume":"55","author":"Chen","year":"2023","journal-title":"Nat Genet"},{"key":"R27-20251029","doi-asserted-by":"crossref","first-page":"1253447","DOI":"10.3389\/fcimb.2023.1253447","article-title":"Gut microbiota causally affects cholelithiasis: a two-sample Mendelian randomization study.","volume":"13","author":"Liu","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"R28-20251029","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/sim.6522","article-title":"Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome.","volume":"34","author":"Greco","year":"2015","journal-title":"Stat Med"},{"key":"R29-20251029","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.thromres.2021.08.026","article-title":"Genetically predicted obesity and risk of deep vein thrombosis.","volume":"207","author":"Tan","year":"2021","journal-title":"Thromb Res"},{"key":"R30-20251029","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression.","volume":"44","author":"Bowden","year":"2015","journal-title":"Int J Epidemiol"},{"key":"R31-20251029","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.semcancer.2020.12.002","article-title":"Metabolic regulation of prostate cancer heterogeneity and plasticity.","volume":"82","author":"Peitzsch","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R32-20251029","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41585-020-0288-x","article-title":"Tumour metabolism and its unique properties in prostate adenocarcinoma.","volume":"17","author":"Bader","year":"2020","journal-title":"Nat Rev Urol"},{"key":"R33-20251029","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12943-024-01968-2","article-title":"Bladder-cancer-derived exosomal circRNA_0013936 promotes suppressive immunity by up-regulating fatty acid transporter protein 2 and down-regulating receptor-interacting protein kinase 3 in PMN-MDSCs.","volume":"23","author":"Shi","year":"2024","journal-title":"Mol Cancer"},{"key":"R34-20251029","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-23-0680","article-title":"Integrative analyses of tumor and peripheral biomarkers in the treatment of advanced renal cell carcinoma.","volume":"14","author":"Choueiri","year":"2024","journal-title":"Cancer Discov"},{"key":"R35-20251029","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.eururo.2023.05.011","article-title":"Checkpoint inhibitors in urothelial carcinoma\u2014future directions and biomarker selection.","volume":"84","author":"Meeks","year":"2023","journal-title":"Eur Urol"},{"key":"R36-20251029","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.cmet.2023.06.005","article-title":"Immunometabolic coevolution defines unique microenvironmental niches in ccRCC.","volume":"35","author":"Tang","year":"2023","journal-title":"Cell Metab"},{"key":"R37-20251029","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1158\/0008-5472.CAN-15-1965","article-title":"Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity.","volume":"76","author":"Pasero","year":"2016","journal-title":"Cancer Res"},{"key":"R38-20251029","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nri3712","article-title":"Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny.","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"R39-20251029","doi-asserted-by":"crossref","first-page":"e006781","DOI":"10.1136\/jitc-2023-006781","article-title":"Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells.","volume":"12","author":"Inkol","year":"2024","journal-title":"J ImmunoTher Cancer"},{"key":"R40-20251029","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00281-016-0592-y","article-title":"The role of dendritic cells in cancer.","volume":"39","author":"Hansen","year":"2016","journal-title":"Semin Immunopathol"},{"key":"R41-20251029","doi-asserted-by":"crossref","first-page":"1338083","DOI":"10.3389\/fimmu.2023.1338083","article-title":"Causal role of immune cells in generalized anxiety disorder: Mendelian randomization study.","volume":"14","author":"Ma","year":"2024","journal-title":"Front Immunol"},{"key":"R42-20251029","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","article-title":"Human FOXP3+ regulatory T cell heterogeneity and function in autoimmunity and cancer.","volume":"50","author":"Wing","year":"2019","journal-title":"Immunity"},{"key":"R43-20251029","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.euo.2019.07.005","article-title":"Plasma metabolomic profiles and risk of advanced and fatal prostate cancer.","volume":"4","author":"Wang","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"R44-20251029","doi-asserted-by":"crossref","first-page":"1558S","DOI":"10.3945\/ajcn.2009.26736E","article-title":"The relation of \u03b1-linolenic acid to the risk of prostate cancer: a systematic review and meta-analysis.","volume":"89","author":"Simon","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"R45-20251029","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nri1710","article-title":"Fuel feeds function: energy metabolism and the T-cell response.","volume":"5","author":"Fox","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"R46-20251029","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3389\/fonc.2019.00490","article-title":"Targeting the tumor microenvironment in renal cell cancer biology and therapy.","volume":"9","author":"Heidegger","year":"2019","journal-title":"Front Oncol"},{"key":"R47-20251029","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12943-022-01597-7","article-title":"Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4\/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer.","volume":"21","author":"Heidegger","year":"2022","journal-title":"Mol Cancer"},{"key":"R48-20251029","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.euo.2020.10.010","article-title":"A systematic review of the emerging role of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: will combination strategies improve efficacy?","volume":"4","author":"Heidegger","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"R49-20251029","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"Prostate cancer screening with PSA, kallikrein panel, and MRI.","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"},{"key":"R50-20251029","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2021.07.024","article-title":"Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European association of urology position and recommendations for 2021.","volume":"80","author":"Van Poppel","year":"2021","journal-title":"Eur Urol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:02:33Z","timestamp":1761746553000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":50,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044282","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"2024-06-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}